KEGG   DRUG: Mogamulizumab
Entry
D09761                      Drug                                   
Name
Mogamulizumab (USAN);
Mogamulizumab (genetical recombination) (JAN);
Mogamulizumab-kpkc;
Poteligeo (TN)
Product
Formula
C6520H10072N1736O2020S42
Exact mass
146352.7047
Mol weight
146442.8849
Sequence
(Heavy chain)
EVQLVESGGD LVQPGRSLRL SCAASGFIFS NYGMSWVRQA PGKGLEWVAT ISSASTYSYY
PDSVKGRFTI SRDNAKNSLY LQMNSLRVED TALYYCGRHS DGNFAFGYWG QGTLVTVSSA
STKGPSVFPL APSSKSTSGG TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
LYSLSSVVTV PSSSLGTQTY ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP
SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSRDEL
TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS KLTVDKSRWQ
QGNVFSCSVM HEALHNHYTQ KSLSLSPGK
(Light chain)
DVLMTQSPLS LPVTPGEPAS ISCRSSRNIV HINGDTYLEW YLQKPGQSPQ LLIYKVSNRF
SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCFQGSLLP WTFGQGTKVE IKRTVAAPSV
FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL
SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
(Disulfide bridge: H22-H96, H146-H202, H222-L219, H228-H'228, H231-H'231, H263-H323, H369-H427, H'B22-H'96, H'146-H'202, H'222-L'219, H'263-H'323, H'369-H'427, L23-L93, L139-L199, L'23-L'93, L'139-L'199)
  Type
Peptide
Remark
Therapeutic category: 4291
ATC code: L01FX09
Product: D09761<JP/US>
Efficacy
Antineoplastic, Anti-CCR4 antibody
  Disease
Mycosis fungoides (CCR4-directed) [DS:H01463]
  Type
Monoclonal antibody
Target
CCR4 (CD194) [HSA:1233] [KO:K04179]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04062  Chemokine signaling pathway
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FX Other monoclonal antibodies and antibody drug conjugates
     L01FX09 Mogamulizumab
      D09761  Mogamulizumab (USAN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Mogamulizumab
    D09761  Mogamulizumab (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D09761  Mogamulizumab (USAN); Mogamulizumab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokine receptors
   Chemokine receptors
    CCR4 (CD194)
     D09761  Mogamulizumab (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D09761
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D09761
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D09761
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D09761
Other DBs
CAS: 1159266-37-1
PubChem: 124490501
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system